Global Biosimilars Market (2018-2022) to Record a CAGR of Approx 35% - ResearchAndMarkets.com
Thursday, 10 January 2019 03:06
Jan. 10, 2019 11:29 UTC

Global Biosimilars Market (2018-2022) to Record a CAGR of Approx 35% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Global Biosimilars Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

The biosimilars market will register a CAGR of almost 35% by 2022.

Patients and physician's willingness to switch to biosimilars is expected to drive growth in the market

Majority of physicians, especially rheumatologists, preferred to prescribe a bio-originator instead of biosimilar as the first line therapy for the treatment. However, the physician and patients are very much willing to shift to biosimilars.

Price advantage of biosimilars over biologics

High cost of biologics reduces patient access to these products and increases the total healthcare costs. The reason for less cost of biosimilar can be sue to the smaller number of clinical trials for a biosimilar when compared with original biologic.

Market access barriers for biosimilars

To compete with biologics and to get entry into the market, the biosimilars are facing challenge. The first and foremost challenge is sophisticated manufacturing process associated with biosimilars.

Key Players

  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY APPLICATION

  • Segmentation by application
  • Comparison by application
  • Oncology and hematology - Market size and forecast 2017-2022
  • Endocrinology - Market size and forecast 2017-2022
  • Immunology - Market size and forecast 2017-2022
  • Nephrology - Market size and forecast 2017-2022
  • Market opportunity by application

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Americas - Market size and forecast 2017-2022
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

  • Patients and physician's willingness to switch to biosimilars
  • Therapeutic interchangeability regulations for biosimilars across countries
  • Biosimilar "patent dance"
  • Many originator companies entering the biosimilar market

PART 14: VENDOR LANDSCAPE

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen
  • Biogen
  • Merck
  • Novartis
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/mnmcjt/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biosimilars and Biosuperiors


Source: Research and Markets




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter